Chimerix’s (CMRX) Outperform Rating Reaffirmed at Wedbush

Wedbush reissued their outperform rating on shares of Chimerix (NASDAQ:CMRXGet Rating) in a report released on Monday morning, Zacks.com reports.

A number of other research analysts have also weighed in on the stock. Maxim Group cut their price target on shares of Chimerix to $6.00 and set a na rating on the stock in a research note on Tuesday. Cowen cut their price target on shares of Chimerix to $10.00 and set a na rating on the stock in a research note on Tuesday. Zacks Investment Research raised shares of Chimerix from a strong sell rating to a hold rating in a research note on Tuesday. HC Wainwright cut their price objective on shares of Chimerix from $24.00 to $11.00 and set a buy rating on the stock in a research report on Monday. Finally, StockNews.com lowered shares of Chimerix from a hold rating to a sell rating in a research report on Saturday, April 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Chimerix has an average rating of Hold and a consensus target price of $9.55.

Shares of NASDAQ CMRX opened at $1.75 on Monday. The stock has a market cap of $153.02 million, a P/E ratio of -1.52 and a beta of 1.28. The firm has a 50 day moving average price of $4.71 and a 200 day moving average price of $5.51. Chimerix has a 52-week low of $1.57 and a 52-week high of $9.29.

Chimerix (NASDAQ:CMRXGet Rating) last announced its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. Chimerix had a negative net margin of 8,753.71% and a negative return on equity of 84.90%. During the same period last year, the company earned ($0.18) EPS. On average, analysts forecast that Chimerix will post -0.15 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace LLP bought a new stake in Chimerix during the third quarter worth $2,667,000. AXA S.A. raised its position in Chimerix by 419.3% during the third quarter. AXA S.A. now owns 206,700 shares of the biopharmaceutical company’s stock worth $1,279,000 after acquiring an additional 166,900 shares in the last quarter. Franklin Resources Inc. bought a new stake in Chimerix during the third quarter worth $256,000. Cambiar Investors LLC raised its position in Chimerix by 24.0% during the fourth quarter. Cambiar Investors LLC now owns 219,062 shares of the biopharmaceutical company’s stock worth $1,409,000 after acquiring an additional 42,456 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in Chimerix by 5.5% during the third quarter. UBS Asset Management Americas Inc. now owns 97,394 shares of the biopharmaceutical company’s stock worth $603,000 after acquiring an additional 5,100 shares in the last quarter. 62.76% of the stock is currently owned by hedge funds and other institutional investors.

About Chimerix (Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

See Also

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.